Oxford Biomedica plc (OXBDF)
- Previous Close
4.4000 - Open
4.6400 - Bid --
- Ask --
- Day's Range
4.4006 - 4.6400 - 52 Week Range
2.0900 - 6.0200 - Volume
300 - Avg. Volume
206 - Market Cap (intraday)
440.06M - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0700 - Earnings Date Apr 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
www.oxb.comRecent News: OXBDF
Performance Overview: OXBDF
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OXBDF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OXBDF
Valuation Measures
Market Cap
415.07M
Enterprise Value
424.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.73
Price/Book (mrq)
4.67
Enterprise Value/Revenue
3.74
Enterprise Value/EBITDA
-6.28
Financial Highlights
Profitability and Income Statement
Profit Margin
-175.89%
Return on Assets (ttm)
-15.08%
Return on Equity (ttm)
-117.29%
Revenue (ttm)
89.54M
Net Income Avi to Common (ttm)
-157.49M
Diluted EPS (ttm)
-2.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
103.72M
Total Debt/Equity (mrq)
143.20%
Levered Free Cash Flow (ttm)
-18.34M